Dr. Shona Milon Nag

Dr. Shona Milon Nag
Medical Oncologist, Pune

MBBS, MD

  • 4 Hospitals
  • Dr. Shona Milon Nag is a Consultant at Curie Manavata Cancer Centre, Nashik, Sahyadri Hospital, Jehangir Hospital, Pune
  • Physician Intensive Care Unit, Inlaks & Budhrani Hospital, Pune,(1991 to 1992)
  • Locum Medical Oncologist for Dr B. R. Smruti, Bombay Hospital Research and Medical Centre, Mumbai, (1994 to 1995)
  • Junior Consultant Medical Oncologist, M. N. Budhrani Cancer Institute, Pune, (1995-1997)
  • Consultant Medical Oncologist, M. N. Budhrani Cancer Institute, Pune
  • Incharge, Tumor Board at Sassoon General Hospital, Pune
  • Consultant Medical Oncologist, Curie Manavata Cancer Centre, Nashik
  • Director, Oncology Services, Sahyadri Hospital, Pune 
  • Chairman- MOG (Maharashtra Oncology Group)
  • Languages :English, Hindi, Marathi

Specialities

  • Medical Oncology

  • Oncology

Expertise

Education

  • MBBS from Pune University, (1982 - 1986)
  • MD(General Medicine) from Pune University, (1988 1990)
  • Fellowship in Medical Oncology, Tata Memorial Hospital/Bombay Hospital(1993 - 1994)
  • Fellowship in Medical Oncology 1998 1999 University of New South Wales
  • Trainee in Medical Oncology, Bombay Hospital Research and Medical Centre, Mumbai, (1993 to 1994)
  • Trainee in Medical Oncology, Tata Memorial Hospital and Research Centre, Mumbai, (1994 Apr-Oct)
  • Oncology Fellow, Cancer Care Centre, St. George Hospital, Sydney, (1998 May-1999)

Practice Information

Curie Manavata Cancer Centre, Nashik

Curie Manavata Cancer Centre, Nashik

Opp. Mahamarg Bus Stand, Mumbai Naka, Nashik, Maharashtra - 422004

Sahyadri Hospital, Deccan Gymkhana

Sahyadri Hospital, Deccan Gymkhana

30C, Erandawane, Karve Road, Deccan Gymkhana, Pune, Maharashtra - 411004

Jehangir Hospital, Pune

Jehangir Hospital, Pune

32, Sassoon Road, Pune, Maharashtra - 411001

Kem Hospital, Pune

Kem Hospital, Pune

Sardar Moodliar Road, , Rasta Peth, Pune, Maharashtra - 411011

Patient Experience

Your participation in the survey will help other patients make informed decisions. You will also be helping Dr. Shona Milon Nag and her staff know how they are doing and how they can improve their services.

Achievements & Contributions

  • GSK-ERI award for ethnic research in breast cancer awarded to Dr Shona Nag, Jehangir Hospital and Dr Sudeep Gupta, Tata Memorial Hospital in Dec 2009 for project on “Distribution of clinical subtypes and associated risk factors for breast cancer in urban Indian women”
  • ISCR award 2010 for best research site – Principal Investigator Dr Shona Nag and JCDC in October 2010, Bangalore
  • Hepatitis B Viral Infection in ALL Nag S., Pai S. K., Advani S. H.;. Indian J. Haem. And Blood Transfusion, 1995; 13:150-3.
  • Oral talactoferrin extends survival in patients with refractory NSCLC in a randomized, placebo-controlled, phase 2 trial: C1-05 Journal of Thoracic Oncology. 12th World Conference on Lung Cancer, Seoul, Korea, September 2-6, 2007. 2(8) Supplement 4:S360, August 2007.
  • Parikh, Purvish M. 1; Wang, Yenyun 2; Ranade, A A. 3; Vaid, A K. 4; Advani, S H. 5; Raghunadharao, D 6; Nag, S 7; Madhavan, J P. 8; Varadhachary, Atul 9Treatment of Advanced Hormone-Sensitive Breast Cancer in Postmenopausal Women With Exemestane Alone or in Combination With CelecoxibLuc Yves Dirix, Jorge Ignacio, Shona Nag, Poonamally Bapsy, Henry Gomez, Digumarti 
  • Raghunadharao, Robert Paridaens, Stephen Jones, Silvia Falcon, Marina Carpentieri, Antonello Abbattista, Jean-Pierre Lobelle Journal of Clinical Oncology Mar 10 2008: 1253-1259
  • A phase II study of sequential neoadjuvant gemcitabine plus doxorubicin followed by gemcitabine plus cisplatin in patients with operable breast cancer: prediction of response using molecular profilingP K Julka1, R T Chacko2, S Nag3, R Parshad1, A Nair2, D S Oh4, Z Hu4, C B Koppiker3, S Nair2, R Dawar1, N Dhindsa5, I D Miller6, D Ma7, B Lin7, B Awasthy8 and C M PerouBritish Journal of Cancer (2008) 98, 1327–1335. Published online 1 April 2008
  • Clinical Experience with Gefitinib in Indian PatientsParikh, Purvish MD *; Chang, Alex Yuang-Chi BM +; Nag, Shona MD ++; Digumarti, Raghunadharao MD [S]; Bhattacharyya, Gouri Shankar MD |; Doval, Dinesh Chandra MD [P]; Babu, Govind MD #; Chacko, Raju Titus MD **; Advani, Suresh MD ++; 
  • Ranade, Anantbhushan MD ++++; Aggarwal, Shyam MD [S][S]; Jagannathan, Ramesh MD ||; Hargreaves, Laura MSc [P][P]; Thatcher, Nick PhD ##Journal of Thoracic Oncology. 3(4):380-385, April 2008
  • Efficacy and Safety of Lapatinib As First-Line Therapy for ErbB2-Amplified Locally Advanced or Metastatic Breast CancerHenry L. Gomez, Dinesh C. Doval, Miguel A. Chavez, Peter C.-S. Ang, Zeba Aziz, Shona Nag, Christina Ng, Sandra X. Franco, Louis W.C. Chow, Michael C. Arbushites, Michelle A. Casey, Mark S. Berger, Steven H. Stein, George W. Sledge Journal of Clinical Oncology Jun 20 2008: 2999-3005
  • Gemcitabine Plus Paclitaxel Versus Paclitaxel Monotherapy in Patients With Metastatic Breast Cancer and Prior Anthracycline TreatmentKathy S. Albain, Shona M. Nag, German Calderillo-Ruiz, Johann P. Jordaan, Antonio C. Llombart, Anna Pluzanska, Janusz Rolski, Allen S. Melemed, Jose M. Reyes-Vidal, Jagdev S. Sekhon, Lorinda Simms, and Joyce O'Shaughnessy Journal of Clinical Oncology Aug 20 2008: 3950–3957
  • Optimizing management of cancer related anemia.K Prabhash, S.Nag, S Patil, PM Parikh.
  • Member - Indian Society of Hematology and Blood Transfusions.
  • Member - American Society of Clinical Oncology (ASCO)
  • Member - European Society of Medical Oncology (ESMO)
  • Member - Indian Collaborative Oncology Network (ICON)
  • Member - Breast Cancer Working Group, Tata Memorial Hospital
  • Member- Advisory Board Astra Zeneca, Bristol Myers Squibb, Biocon, Glaxo Smithkline